At what enterprise value was CERBA HEALTHCARE acquired in 2017?

During the acquisition of CERBA HEALTHCARE by PARTNERS GROUP / PSP INVESTMENTS in 2017, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of CERBA HEALTHCARE when it was acquired by PARTNERS GROUP / PSP INVESTMENTS?

The estimated EV/EBITDA multiple for CERBA HEALTHCARE is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

What was the revenue of CERBA HEALTHCARE at the time of the deal?

The revenue of CERBA HEALTHCARE at the time of the deal is estimated to be in the range of 450M - 900M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of CERBA HEALTHCARE during the acquisition?

CERBA HEALTHCARE's EBITDA is estimated to be in the range of 100M - 200M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the CERBA HEALTHCARE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the CERBA HEALTHCARE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.partnersgroup.com/news-and-views/press-releases/investment-news/detail?news_id=9cb940f3-29fb-42b1-958e-c620148a546c

← DATABASE

Home Database Healthcare & PharmaCERBA HEALTHCARE

01/2017

CERBA HEALTHCARE acquired by PARTNERS GROUP & PSP INVESTMENTS

FRANCE Health Providers / Healthcare Facilities / Labs (Biology) EV 1b - 4b EUR

Context

Partners Group and Canadian pension fund PSP entered exclusive negotiations to acquire Cerba from PAI Partners. The consortium beat out CVC and Apax, but most notably rejected a higher offer (>EUR2bn) from industrial player Cinven (owner of Synlab/Labco). Management preferred the financial sponsors to avoid massive cost synergies and restructuring.

In the past, the company underwent an LBO led by Pai Partners in 2010, and continued an active consolidation strategy by notably acquiring Novescia (2015).

CERBA HEALTHCARE, which reported an EBITDA margin of in 2016, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Cerba HealthCare is a leading international network of clinical pathology laboratories. Headquartered in France, it operates across Europe and Africa. The group serves patients, physicians, and pharmaceutical companies (via its clinical trial division). It relies on a network of 400 biologists and managers who are also shareholders.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2016

2015

Other operations with CERBA HEALTHCARE

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
09/2023	CERBA HEALTHCARE	CIRION BIOPHARMA RESEARCH	CANADA	CRO / Clinical Trials
11/2021	CERBA HEALTHCARE	LABEXA	FRANCE	Labs (Biology)
07/2021	CERBA HEALTHCARE	LIFEBRAIN	ITALY	Labs (Biology)
03/2021	EQT PARTNERS	CERBA HEALTHCARE	FRANCE	Labs (Biology)
01/2015	CERBA HEALTHCARE	NOVESCIA	FRANCE	Labs (Biology)
06/2010	PAI PARTNERS	CERBA HEALTHCARE	FRANCE	Labs (Biology)

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 450M - 900M EUR

EBITDA range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of CERBA HEALTHCARE by PARTNERS GROUP / PSP INVESTMENTS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: cerba healthcare

Acquirer: psp investments / partners group